Table 5 Other outcomes
Study | ARMS (N patients) | DFS | OS | Compliance** | AEs* | Post-operative complications | |
|---|---|---|---|---|---|---|---|
LCRT | TNT | ||||||
EudraCT | EXP. ARM (28) | – | – | 23 (86%) | 27 (95%) | 10 (36%) | 7 (25%) |
CONTROL (29) | 28 (97%) | – | 2 (7%) | 9 (31%) | |||
GCR-3 | EXP. ARM (56) | 62%1 | 75%1 | 42 (78%) | 51 (94%) | 12 (23%) | 27 (51%) |
CONTROL (52) | 64%1 | 78%1 | 46 (94%) | – | 15 (29%) | 21 (45%) | |
POLISH II | EXP. ARM (261) | 53%2 | 73%2 | – | 23% | 29% | |
CONTROL (254) | 52%2 | 65%2 | 21% | 25% | |||
WAIT | EXP. ARM (25) | – | – | – | – | – | |
CONTROL (24) | |||||||
KCSG CO 14-03 | EXP. ARM (53) | – | – | – | 5 (9%) | 4 (9%) | |
CONTROL (55) | 2 (4%) | 1 (2%) | |||||
FOWARC | ARM TNT + RT (165) | 78%2 | 90%2 | – | – | – | |
ARM TNT (165) | 74%2 | 91%2 | |||||
CONTROL (165) | 73%2 | 91%2 | |||||
RAPIDO | EXP. ARM (462) | ₮ | 89%2 | – | 84% | – | 50% |
CONTROL (450) | 89%2 | 93% | – | 47% | |||
PRODIGE-23 | EXP. ARM (231) | 76%2 | 91%2 | 219 (95%) |  > 90% | 73 (45%) | – |
CONTROL (230) | 69%2 | 88%2 | 227 (99%) | – | 117 (74%) | ||